Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Validation and Mechanism Study of CACNA1A as a Biomarker for Antidepressant Efficacy
ChiCTR2600129527Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of fluoxetine, venlafaxine and duloxetine in major depressive disorder (MDD) (3 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: HAMD-17 total score change at 8 weeks and Baseline CACNA1A RNA expression level. Started Aug 2026; status: recruiting.
02
Drugs
fluoxetinevenlafaxineduloxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2600129527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129527.